Using absolute prostate-specific antigen (PSA) thresholds to make decisions about diagnostic testing and biopsies remains controversial (Journal Watch Top Story Dec 31 2004), but PSA velocity (the ...

We need better ways to determine which prostate-specific antigen (PSA)-detected localized prostate cancers are most likely to progress. The rate at which the PSA level rises (i.e., PSA velocity) prior ...

We conducted a systematic review of studies published before March 2007 in which a PSA dynamic (velocity or doubling time) was calculated in patients before definitive treatment, a subsequent event ...

A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, ...

Arnhem, November 2009 – The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity ...

Elevated serum prostate-specific antigen (PSA) levels can indicate the presence of prostate cancer, although PSA levels are also elevated in some nonmalignant conditions, which affects the reliability ...

Serum PSA values >4.0 ng/ml are routinely used to select patients for prostate biopsy, although this approach misses some early-stage cancers. Some researchers advocate dropping the PSA threshold to 2 ...

If you need further proof that medicine is just as much art as science, a new study shows that some common sense needs to prevail before rushing into possibly unnecessary prostate biopsies if there is ...

The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study. Published in the July 1, 2007 ...

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early ...

GAITHERSBURG, Md., May 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early ...

To the Editor: There are some basic methodologic flaws in the work by D'Amico et al. (July 8 issue). 1 In their multivariate analyses, the prostate-specific antigen (PSA) velocity was modeled as a ...